Shin Kasai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shin Kasai has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Kumiko Goi
Department of Pediatrics, School of Medicine University of Yamanashi Chuo Japan
5 shared publications- Koshi Akahane
Department of Pediatrics, School of Medicine University of Yamanashi Chuo Japan
4 shared publications - Atsushi Watanabe
Department of Pediatrics, School of Medicine University of Yamanashi Chuo Japan
3 shared publications Keiko Kagami
Department of Pediatrics, School of Medicine University of Yamanashi Chuo Japan
3 shared publications- Minori Tamai
Department of Pediatrics, School of Medicine University of Yamanashi Chuo Japan
3 shared publications - Takeshi Inukai
Department of Pediatrics, School of Medicine University of Yamanashi Chuo Japan
3 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72386
Impact of p53 Target Genes on Drug Resistance in TP53 ‐Mutated B‐Cell Precursor Acute Lymphoblastic Leukemia
TP53 mutations are linked to poor prognoses in B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), indicating that specific p53 target genes may contribute to drug resistance. Although the impact of specific genetic alterations on drug sensitivity has been reported in BCP‐ALL, the effects of TP53 mutations on sensitivity to individual agents remain poorly defined in the clinical setting because of the use of combination chemotherapy regimens. In the present study, we addressed this issue through two complementary analyses using a large panel of BCP‐ALL cell lines. Initially, 30 cell lines harboring TP53 mutations demonstrated significantly greater resistance to daunorubicin (DNR), mafosfamide (MAF; an active analog of cyclophosphamide), 6‐mercaptopurine (6‐MP), and prednisolone compared to 46 cell lines without mutations. Second, 11 CRISPR/Cas9‐mediated TP53 ‐knockout sublines derived from cell lines with wild‐type TP53 recapitulated resistance to DNR, MAF, and 6‐MP, as well as to vincristine (VCR) and cytarabine (Ara‐C). Consistent with these findings, re‐evaluation of genome‐wide CRISPR screening datasets revealed significant enrichment of TP53 gRNAs in cells treated with DNR, MAF, 6‐MP, Ara‐C, and VCR. Furthermore, transcriptomic and proteomic analyses of p53 target genes in the two cell line models, along with re‐evaluation of genome‐wide CRISPR screening datasets, identified BAX , BBC3 , and FDXR as key p53 target genes associated with multidrug resistance. These results highlight the potential value of targeting these p53 downstream pathways to improve outcomes in TP53 ‐mutated BCP‐ALL cases.
- 13 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72386
Open AccessImpact of p53 Target Genes on Drug Resistance in TP53 ‐Mutated B‐Cell Precursor Acute Lymphoblastic Leukemia
TP53 mutations are linked to poor prognoses in B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), indicating that specific p53 target genes may contribute to drug resistance. Although the impact of specific genetic alterations on drug sensitivity has been reported in BCP‐ALL, the effects of TP53 mutations on sensitivity to individual agents remain poorly defined in the clinical setting because of the use of combination chemotherapy regimens. In the present study, we addressed this issue through two complementary analyses using a large panel of BCP‐ALL cell lines. Initially, 30 cell lines harboring TP53 mutations demonstrated significantly greater resistance to daunorubicin (DNR), mafosfamide (MAF; an active analog of cyclophosphamide), 6‐mercaptopurine (6‐MP), and prednisolone compared to 46 cell lines without mutations. Second, 11 CRISPR/Cas9‐mediated TP53 ‐knockout sublines derived from cell lines with wild‐type TP53 recapitulated resistance to DNR, MAF, and 6‐MP, as well as to vincristine (VCR) and cytarabine (Ara‐C). Consistent with these findings, re‐evaluation of genome‐wide CRISPR screening datasets revealed significant enrichment of TP53 gRNAs in cells treated with DNR, MAF, 6‐MP, Ara‐C, and VCR. Furthermore, transcriptomic and proteomic analyses of p53 target genes in the two cell line models, along with re‐evaluation of genome‐wide CRISPR screening datasets, identified BAX , BBC3 , and FDXR as key p53 target genes associated with multidrug resistance. These results highlight the potential value of targeting these p53 downstream pathways to improve outcomes in TP53 ‐mutated BCP‐ALL cases.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70087
Multifocal osteonecrosis as well as repeated bone fractures due to osteoporosis in a prepubertal ALL case
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70087
Multifocal osteonecrosis as well as repeated bone fractures due to osteoporosis in a prepubertal ALL case
- Open Access
- 12 January 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (4) , e30868
In utero tumor development and identification of CTNNB1 mutation in a newborn case of ossifying renal tumor of infancy
- 12 January 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (4) , e30868
Open AccessIn utero tumor development and identification of CTNNB1 mutation in a newborn case of ossifying renal tumor of infancy
- 6 May 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (4) , 534-543
Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system
Imatinib and second-generation tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, overcoming TKI resistance due to the T315I gatekeeper mutation of BCR/ABL1 is crucial for further improving the prognosis. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is appropriate for establishing a human model of Ph+ ALL with the T315I mutation, because it can induce specific mutations via homologous recombination (HR) repair in cells with intact endogenous HR pathway. Here we used CRISPR/Cas9 to introduce the T315I mutation into the Ph+ lymphoid leukemia cell line KOPN55bi, which appeared to have an active HR pathway based on its resistance to a poly (ADP-Ribose) polymerase-1 inhibitor. Single-guide RNA targeting at codon 315 and single-strand oligodeoxynucleotide containing ACT to ATT nucleotide transition at codon 315 were electroporated with recombinant Cas9 protein. Dasatinib-resistant sublines were obtained after one-month selection with the therapeutic concentration of dasatinib, leading to T315I mutation acquisition through HR. T315I-acquired sublines were highly resistant to imatinib and second-generation TKIs but moderately sensitive to the therapeutic concentration of ponatinib. This authentic human model is helpful for developing new therapeutic strategies overcoming TKI resistance in Ph+ ALL due to T315I mutation.
- 6 May 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (4) , 534-543
Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system
Imatinib and second-generation tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, overcoming TKI resistance due to the T315I gatekeeper mutation of BCR/ABL1 is crucial for further improving the prognosis. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is appropriate for establishing a human model of Ph+ ALL with the T315I mutation, because it can induce specific mutations via homologous recombination (HR) repair in cells with intact endogenous HR pathway. Here we used CRISPR/Cas9 to introduce the T315I mutation into the Ph+ lymphoid leukemia cell line KOPN55bi, which appeared to have an active HR pathway based on its resistance to a poly (ADP-Ribose) polymerase-1 inhibitor. Single-guide RNA targeting at codon 315 and single-strand oligodeoxynucleotide containing ACT to ATT nucleotide transition at codon 315 were electroporated with recombinant Cas9 protein. Dasatinib-resistant sublines were obtained after one-month selection with the therapeutic concentration of dasatinib, leading to T315I mutation acquisition through HR. T315I-acquired sublines were highly resistant to imatinib and second-generation TKIs but moderately sensitive to the therapeutic concentration of ponatinib. This authentic human model is helpful for developing new therapeutic strategies overcoming TKI resistance in Ph+ ALL due to T315I mutation.
- 1 December 2018
- Published by Elsevier in Leukemia Research
- Vol. 75, 36-44
Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements
- 1 December 2018
- Published by Elsevier in Leukemia Research
- Vol. 75, 36-44
Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements